Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792451 · ClinicalTrials.gov registry record
Nutrition Status of Adults Treated With Pegvaliase
A clinical trial, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 18
- Enrollment target
NCT03792451: Completed study, sponsored by Boston Children's Hospital.
NCT03792451 is a clinical trial that has completed, run by Boston Children's Hospital. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03792451 has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
Conduct a cross-sectional analysis of the nutritional status of individuals with PKU treated with pegvaliase for one or more years or who have followed an unrestricted diet for 6 or more months while on pegvaliase treatment. We will evaluate laboratory markers of nutritional status, including markers of protein and micronutrient nutriture. In addition, a three-day food record and food frequency questionnaire will be obtained to assess protein intake and overall diet quality.
Interventions
- DRUG Pegvaliase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2020-12-31 |
What the finished NCT03792451 record still lists
NCT03792451 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pegvaliase is the first listed.
NCT03792451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03792451 about?
NCT03792451 is a clinical study titled "Nutrition Status of Adults Treated With Pegvaliase". Conduct a cross-sectional analysis of the nutritional status of individuals with PKU treated with pegvaliase for one or more years or who have followed an unrestricted diet for 6 or more months while on pegvaliase treatment. We will evaluate laboratory markers of nutritional status, including marker...
What is the current status of trial NCT03792451?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2019-01-17. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03792451?
The interventions under investigation include: Pegvaliase (DRUG).
Who is sponsoring clinical trial NCT03792451?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI